X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.businesswire.com/news/home/20231220302305/en/Merck-Provides-U.S.-Regulatory-Update-on-Gefapixant
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-panel-votes-against-mercks-chronic-cough-drug-2023-11-17/
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-staff-flags-concerns-mercks-chronic-cough-drug-2023-11-15/
https://www.fiercebiotech.com/biotech/ahead-tomorrows-adcomm-fda-skeptical-mercks-gefapixant-even-after-pharma-recounted-coughs
https://www.ema.europa.eu/en/documents/overview/lyfnua-epar-medicine-overview_en.pdf
https://www.fiercebiotech.com/biotech/gsk-coughs-2b-stop-coughs-buying-bellus-late-phase-rival-mercks-stuttering-therapy#:~:text=Merck%20%26%20Co.%20has%20a%20new,year%20turnaround%20for%20the%20biotech
https://www.fiercebiotech.com/biotech/merck-plans-count-coughs-and-months-until-gefapixant-back-fda-hands
https://www.merck.com/news/merck-provides-u-s-and-japan-regulatory-update-for-gefapixant/
http://www.pharmatimes.com/news/higher_dose_of_gefapixant_hits_endpoints_in_chronic_cough_trial_1329472
https://www.prnewswire.com/news-releases/compugen-announces-closing-of-75-million-public-offering-of-ordinary-shares-301025440.html
Market Place
Share 
